Pharmaceutical Mundipharma and its independent associated company, USA-based Purdue Pharma, today announced that, following completion of Phase II studies, they have exercised their option and taken over full responsibility from Spain’s Laboratorios Esteve for the clinical, regulatory and commercial development of a potential first-in-class sigma-1 antagonist (S1A or MR309/E-52862). 16 May 2016